Table 1.
Selected JAKinibs
Agent | Targets | Indication/Phase |
---|---|---|
Tofacitinib | JAK3/JAK1/JAK2 | RA/Phase III Psoriasis/Phase II IBD/Phase II |
VX-509 | JAK3 | RA/Phase II |
R-348 | JAK3 | RA/Phase I |
Ruxolitinib | JAK1/JAK2 | Approved – MF/PV |
INCB-28050 | JAK1/JAK2 | RA/Phase II |
GLPG-0634 | JAK1 | RA/Phase II |
AC-430 | JAK2 | RA/Phase I Lymphoma/Phase I |
Lestaurtinib | FLT3/TrkA/JAK2 | AML/Phase III Psoriasis/Phase II Pancreatic cancer/Phase II |
CEP-33779 | JAK2 | Preclinical |